http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
강력한 HIV 약물치료의 현주소-신약과 기존약 무엇이 다른가
김효열,Kim, Hyo-Yeol 대한에이즈예방협회 2007 레드리본 Vol.75 No.-
에이즈 치료제로 강력한 항레트로바이러스 치료(highly active antiretroviral therapy;HAART)가 시작된 지 10년이 지났다. 그동안 효과적인 항레트로바이러스제의 가지 수도 늘었지만 좀 더 먹기 편하고, 부작용이 적은 약제 개발로 많은 발전이 있어왔다. HIV감염에 대한 최상의 치료는 효과적인 항레트로바이러스제를 적어도 3가지 약제 이상, 또한 2가지 계열 이상 병용하여 사용하는 칵테일요법이다. 현재의 이 약물치료는 효과적으로 에이즈 바이러스를 억제하고 기회 질환의 발생이나 사망을 현저하게 줄이는데 공헌하였다. 그러나 아직까지는 완치의 개념에는 도달하지 못하고 있다. 항레트로바이러스제의 적절한 사용은 혈중 HIV를 검출한계 미만으로 억제할 수 있고, CD4+ 림프구의 수를 증가시키는 치료효과를 보이지만 부수적으로 소수의 부작용이 동반될 수 있다. 여기서는 최근 국내에 들어와 있지 않거나 임상시험이 진행 중인 신약들과 기존 약제들 간의 차이점을 소개하고자 한다.
송복현(Bok Hyun Song),이은규(Eun Kyu Lee),박송이(Song I Park),김효열(Hyo Yeol Kim) 대한두경부종양학회 2020 대한두경부 종양학회지 Vol.36 No.2
Myoepithelioma is a rare benign neoplasm that mostly arises in the major salivary glands and sometimes in the minor salivary glands, which account only for less than 1% of all salivary glands neoplasms. However, its extra-salivary involvement is even rarer and only a few cases of nasal cavity myoepithelioma were reported in the English-language literature so far. In this case report, we present a 40-year-old female with unilateral nasal obstruction diagnosed as myoepithelioma of the nasal septum and treated with endoscopic sinus surgery.
장우익 ( Jang U Ig ),안강현 ( An Gang Hyeon ),이종인 ( Lee Jong In ),김현수 ( Kim Hyeon Su ),김효열 ( Kim Hyo Yeol ),김수경 ( Kim Su Gyeong ),이동기 ( Lee Dong Gi ),배선우 ( Bae Seon U ),심영학 ( Sim Yeong Hag ),강명서 ( Kang Myeo 대한내과학회 1993 대한내과학회지 Vol.44 No.4
Background: Detection of tumor markers could offer an accessible method for screening risk groups in order to achieve an early diagnosis of cansers, to contribute to and adequate staging, and to help evaluate effects of therapy. CA 125 is an antigenic determinant defined by murine monoclonal antibody OC 125, and synthesized by coelomic epithelial derivatives such as Mullerian epithelium and mesothelial tissues. CA 125 is regarded as useful tumor marker for non-musinous epithelial ovarian tumors. So we investigated whether CA 125 is reliable tumor marker for gastrointestinal malignancies and especially for detection of intraperitoneal carcinomatosis unrecognized by conventional imaging studies. And we compared CA 125 with other conventional tumor markers in the serodiagnosis of gastrointestinal malignancies. Methods: Serum CA 72-4, CA 19-9, CA 125 and CEA were determined radioimmunologically with monoclonal antibodies. A cut-off value of 4 U/ml, 37 U/ml, 35 U/ml and 5 mg/ml were used respectively. Results: The results are summarized as follows. 1) CA 125 had high specificity (93%) for benign gastrointestinal disease but was not useful to differetiate malignant ascites and benign ascites. 2) In gastric carcinoma, the sensitivity of CA 125 (36%) was not so different to that of CA 72-4(36%). 3) In pancreatobiliary carcinoma, the sensitivity of CA 125(55%) was inferior than that of CA 19-9 (85%), but combined use of these two tumor markers increases sensitivitu(95%) for the diagnosis. 4) The sensitivities of CA 125 for 23 early gastric cancer was 9%. 5) The sensitivities of CA 125 for the intraperitoneal carcinomatosis that was not recognized by conventional imaging studies was 36%. Conclustion: Our data indicates that CA 125 is not better in the serodiagnosis of gastrointestinal malignancies than other conventional tumor markers, and CA 125 has a little predictive value in the diagnosis of intraperitoneal carcinomatosis unrecognized by the conventional imaging studies. Serum CA 125 elevation in benign or malignant diseases closely correlated with the presence of ascites.
Human immunodeficiency virus(HIV) 감염자에 있어서 3제 병용요법의 치료효과 및 안전성
홍성관(Sung Kwan Hong),박윤수(Yoon Soo Park),조정호(Jeong Ho Cho),노현정(Hyun Jung Roh),김효열(Hyo Yeol Kim),장경희(Kyung Hee Chang),송영구(Young Goo Song),김준명(June Myung Kim) 대한내과학회 2000 대한내과학회지 Vol.58 No.5
Background : Antiretroviral combination therapy with one protease inhibitor and two reverse transcriptase inhibitors is profoundly suppressive of HIV replication. To determine the efficacy and safety of the triple combination therapy in persons with HIV infection in Korea, we analyzed the response of therapy in terms of immunity and viral load. Methods : Ten persons with HIV infection, who were treated with triple combination therapy at least 12 months at Yonsei University College of Medicine from 1997 to 1999 were studied. The triple combination therapy regimen consisted of two reverse transcriptase inhibitors (zidovudine or didanosine, lamivudine) and one protease inhibitor (indinavir). We analyzed the levels of HIV RNA, CD4+ cell counts, β2MG, and p24Ag before and after treatment. Adverse drug reactions during therapy were described. Results : The mean age of patients at treatment was 38.7 years. Nine patients were male, and 1 patient was female. Six patients received triple combination therapy as initial treatment, while 4 patients received it as re-treatment. The mean level of HIV RNA was 129,222 copies/mm3 before treatment. RNA level decreased to less than 500 copies/mm3 (non-detectable range) at 1 month in 7 of 10 patients, at 12 months in 9 of 10 patients. The mean CD4+ cell counts was 206/mm3 before treatment, and 376/mm3 after 12 months treatment. The β2MG decreased to 2.7 mg/L from 2.8 mg/L after 12 months of treatment. The p24Ag was positive in 3 of 10 patients and negative in all of the patients at 3 months treatment. Mild hyperbilirubinemia (5 cases) was the most frequent adverse reaction followed by flank pain (3 cases), skin rash (2 cases), abdominal discomfort (2 cases), and mild elevation of AST/ALT (1 case). Conclusion : The triple combination therapy in HIV infection appeared to be generally well tolerated, and was able to profoundly sustain suppression of HIV replication.(Korean J Med 58:582-589, 2000)
강용석 ( Yong Seok Kang ),하성삼 ( Seong Sam Ha ),성재호 ( Jae Ho Seong ),한용재 ( Yong Jae Han ),임유리 ( Yoo Li Lim ),이태식 ( Tae Sic Lee ),김효열 ( Hyo Yeol Kim ),김영근 ( Young Keun Kim ),김종구 ( Jong Koo Kim ),박연철 ( Yon 전북대학교 의과학연구소 2014 全北醫大論文集 Vol.38 No.2
Indeterminate western blot in HIV infection can be due to seroconversion during acute HIV infection, advanced HIV infection or infection with HIV-2. In this report, we describe a patient whose advanced HIV infection was identified by a positive combined antigen/ antibody test and detectable viremia, with an inch of being misdiagnosed as acute HIV syndrome. A 23-year-old male was admitted with fever, myalgia, diarrhea and weight loss. He denied previous history of HIV infection, sexual contact and transfusion. Indeterminate western blot result made us misdiagnosis as a seroconversion in acute HIV syndrome. He denied his disease and insisted to delay antiretroviral therapy until positive western blot results. We had question about very low CD4 cell count (22/uL), and asked HIV/AIDS national registry for his previous registration. He was diagnosed HIV infection via blood donor screening 22 months before admission, but was not informed of the result. Finally the patient was confirmed advanced HIV infection and started antiretroviral therapy.